Cargando…
A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, accounting for the majority of breast cancer-related death. Due to the lack of specific therapeutic targets, chemotherapeutic agents (e.g., paclitaxel) remain the mainstay of systemic treatment, but enrich a subpop...
Autores principales: | El-Sahli, Sara, Hua, Khang, Sulaiman, Andrew, Chambers, Jason, Li, Li, Farah, Eliya, McGarry, Sarah, Liu, Dan, Zheng, Peiyong, Lee, Seung-Hwan, Cui, Jiefeng, Ekker, Marc, Côté, Marceline, Alain, Tommy, Li, Xuguang, D’Costa, Vanessa M., Wang, Lisheng, Gadde, Suresh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791049/ https://www.ncbi.nlm.nih.gov/pubmed/33414428 http://dx.doi.org/10.1038/s41419-020-03308-w |
Ejemplares similares
-
Editorial for Special Issue “Cancer Treatment via Nanotherapy”
por: Wang, Lisheng
Publicado: (2023) -
Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells
por: Sulaiman, Andrew, et al.
Publicado: (2018) -
Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells
por: Sulaiman, Andrew, et al.
Publicado: (2020) -
Dual inhibition of Wnt and Yes‐associated protein signaling retards the growth of triple‐negative breast cancer in both mesenchymal and epithelial states
por: Sulaiman, Andrew, et al.
Publicado: (2018) -
Ormeloxifene nanotherapy for cervical cancer treatment
por: Chauhan, Neeraj, et al.
Publicado: (2019)